These results suggest that the total number of CTCs and CD90(+) and EpCAM(+) CTCs may be accurate biomarkers of clinical response during the course of treatment of patients with HCC receiving Atezo-Bev therapy. Here, THY1 is linked to hepatocellular carcinoma.